孟鲁司特钠联合布地奈德治疗小儿哮喘的临床疗效分析(1)
摘 要：目的 探讨小儿哮喘应用孟鲁司特钠与布地奈德联合治疗的疗效。方法 选取本院儿科2014年7月～2015年7月接收治疗的110例哮喘患儿，随机分为甲组和乙组，各55例。甲组患儿单纯应用布地奈德进行治疗，乙组患儿在甲组治疗的同时联合应用孟鲁司特钠，对比两组哮喘患儿的肺功能、炎性情况以及临床疗效。结果 ①乙组治疗后的FEV1、FVC与PEF依次为(0.89±0.20)L、(0.83±0.19)L、(90.00±18.20)L/s，均分别高于甲组的(0.78±0.30)L、(0.65±0.20)L、(81.20±21.00)L/s，差异有统计学意义(P<0.05)。②乙组治疗后的hs-CRP、IL-6依次为(8.00±1.29)mg/L、(44.00±12.40)pg/ml，分别低于甲组的(11.30±2.00)mg/L、(95.68±16.55)pg/ml，差异有统计学意义(P<0.05)。③乙组治疗总有效率为90.91%，高于甲组的72.73%，差异有统计学意义(P<0.05)。结论 对哮喘患儿应用孟鲁司特钠与布地奈德联合治疗，有助于缓解呼吸道炎性症状、改善肺功能，促进临床疗效的进一步提升。
, http://www.100md.com
关键词：孟鲁司特钠；布地奈德；小儿哮喘
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.038
文章编号：1006-1959(2018)13-0131-03
Abstract：Objective To evaluate the efficacy of montelukast sodium combined with budesonide in the treatment of childhood asthma. Methods 110 children with asthma received treatment from July 2014 to July 2015 were randomly divided into two groups：group A (55 cases)and group B(55 cases).Group A was treated with budesonide alone，group B was treated with montelukast sodium in combination with group A，and the pulmonary function，inflammatory status and clinical efficacy of two groups of asthmatic children were compared.Results ①After treatment，FEV1，FVC and PEF in group B were(0.89±0.20)L，(0.83±0.19)L，(90.00±18.20)L/s， respectively，higher than those in group A(0.78±0.30)L，(0.65±0.20)L，(81.20±21.00)L/s，respectively，the difference was statistically significant (P< 0.05).②After treatment，hs-CRPN，IL-6 in group B was (8.00±1.29)mg/L，(44.00±12.40)pg/ml，respectively，lower than that in group A(11.30 ±2.00)mg/L，(95.68 ±16.55)pg/ml，the difference was statistically significant (P<0.05).③The total effective rate of treatment in group B was 90.91%，which was higher than that in group A 72.73%，the difference was statistically significant(P<0.05). Conclusion The combined therapy of montelukast sodium and budesonide is helpful to relieve respiratory inflammatory symptoms， improve lung function and promote the further improvement of clinical efficacy in asthmatic children.
, 百拇医药
Key words：Montelukast sodium；Budesonide；Childhood asthma
小兒哮喘(childhood asthma)作为儿科临床常见病与多发病，临床上多以选择药物治疗为主，孟鲁司特钠与布地奈德均为常用药物[1]。两种药物单独给药均可以发挥一定的治疗效果，但在联合用药方面的研究不多，鉴于此，为进一步分析孟鲁司特钠与布地奈德联合治疗小儿哮喘的效果，本次研究随机抽取了本院儿科2014年7月～2015年7月接收治疗的110例哮喘患儿展开详细分组分析，并将研究结果详细报道如下。
1资料与方法
1.1一般资料 选取2014年7月～2015年7月成都市武侯区人民医院小儿呼吸内科接收治疗的110例哮喘患儿，所有程序通过本院伦理委员会审批。采用随机数字表法将患儿分为甲组和乙组，每组55例。甲组中，女性患儿25例，男性患儿30例；年龄3～12岁，平均年龄(5.02±2.11)岁；病程5个月～4年，平均病程(2.51±0.20)年。乙组中，女性患儿26例，男性患儿29例；年龄3～13岁，平均年龄(5.51±2.02)岁；病程4个月～4年，平均病程(2.42±0.31)年。两组患儿性别、年龄、病程等一般资料相比，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(张明荣)
, http://www.100md.com
关键词：孟鲁司特钠；布地奈德；小儿哮喘
中图分类号：R725.6 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.13.038
文章编号：1006-1959(2018)13-0131-03
Abstract：Objective To evaluate the efficacy of montelukast sodium combined with budesonide in the treatment of childhood asthma. Methods 110 children with asthma received treatment from July 2014 to July 2015 were randomly divided into two groups：group A (55 cases)and group B(55 cases).Group A was treated with budesonide alone，group B was treated with montelukast sodium in combination with group A，and the pulmonary function，inflammatory status and clinical efficacy of two groups of asthmatic children were compared.Results ①After treatment，FEV1，FVC and PEF in group B were(0.89±0.20)L，(0.83±0.19)L，(90.00±18.20)L/s， respectively，higher than those in group A(0.78±0.30)L，(0.65±0.20)L，(81.20±21.00)L/s，respectively，the difference was statistically significant (P< 0.05).②After treatment，hs-CRPN，IL-6 in group B was (8.00±1.29)mg/L，(44.00±12.40)pg/ml，respectively，lower than that in group A(11.30 ±2.00)mg/L，(95.68 ±16.55)pg/ml，the difference was statistically significant (P<0.05).③The total effective rate of treatment in group B was 90.91%，which was higher than that in group A 72.73%，the difference was statistically significant(P<0.05). Conclusion The combined therapy of montelukast sodium and budesonide is helpful to relieve respiratory inflammatory symptoms， improve lung function and promote the further improvement of clinical efficacy in asthmatic children.
, 百拇医药
Key words：Montelukast sodium；Budesonide；Childhood asthma
小兒哮喘(childhood asthma)作为儿科临床常见病与多发病，临床上多以选择药物治疗为主，孟鲁司特钠与布地奈德均为常用药物[1]。两种药物单独给药均可以发挥一定的治疗效果，但在联合用药方面的研究不多，鉴于此，为进一步分析孟鲁司特钠与布地奈德联合治疗小儿哮喘的效果，本次研究随机抽取了本院儿科2014年7月～2015年7月接收治疗的110例哮喘患儿展开详细分组分析，并将研究结果详细报道如下。
1资料与方法
1.1一般资料 选取2014年7月～2015年7月成都市武侯区人民医院小儿呼吸内科接收治疗的110例哮喘患儿，所有程序通过本院伦理委员会审批。采用随机数字表法将患儿分为甲组和乙组，每组55例。甲组中，女性患儿25例，男性患儿30例；年龄3～12岁，平均年龄(5.02±2.11)岁；病程5个月～4年，平均病程(2.51±0.20)年。乙组中，女性患儿26例，男性患儿29例；年龄3～13岁，平均年龄(5.51±2.02)岁；病程4个月～4年，平均病程(2.42±0.31)年。两组患儿性别、年龄、病程等一般资料相比，差异无统计学意义(P>0.05)，具有可比性。, 百拇医药(张明荣)